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Abstract
Background: Limited data from positron emission tomography (PET) studies of subjects with
attention-deficit/hyperactivity disorder (ADHD) indicate alterations in brain dopamine
neurotransmission. However, these studies have used conventional univariate approaches that are
less sensitive to detect complex interactions that may exist between different brain dopamine
pathways and individual symptoms of ADHD. We aimed to investigate these potential interactions
in adolescents with ADHD.
Methods:  We used a 3D PET scan to measure utilization of native L-[11C]-DOPA to map
dopamine presynaptic function in various cortical, striatal and midbrain regions in a group of 8 male
adolescents with ADHD and 6 age matched controls. To evaluate the interactions between the
studied brain regions, multivariate statistical methods were used.
Results: Abnormal dopaminergic function was found in multiple brain regions of patients with
ADHD. A main finding was lower L-[11C]-DOPA utilization in adolescent with ADHD as compared
to control subjects, especially in subcortical regions. This pattern of dopaminergic activity was
correlated specifically with symptoms of inattention.
Conclusion: Dopamine signalling in the brain plays an important modulatory role in a variety of
motor and cognitive functions. We have identified region-specific functional abnormalities in
dopaminergic function, which may help better account for the symptoms of ADHD.
Background
Attention deficit hyperactivity disorder (ADHD) is a com-
mon neurodevelopmental disorder characterized by diffi-
culties associated with attention, motor hyperactivity and
impulsivity. The inappropriate behaviour is related to def-
icits of executive functions including working memory,
response inhibition and motor timing [1-7]. Neural cir-
cuits in the frontal cortex and in the basal ganglia, inner-
vated by dopamine neurons originating from the
midbrain, are involved in the control of these executive
functions. A large number of studies have shown that
robust doses of psychostimulants reduce the symptoms of
Published: 04 December 2006
Behavioral and Brain Functions 2006, 2:40 doi:10.1186/1744-9081-2-40
Received: 13 July 2006
Accepted: 04 December 2006
This article is available from: http://www.behavioralandbrainfunctions.com/content/2/1/40
© 2006 Forssberg et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Behavioral and Brain Functions 2006, 2:40 http://www.behavioralandbrainfunctions.com/content/2/1/40
Page 2 of 10
(page number not for citation purposes)
ADHD in about 80% of those prescribed the drugs [8].
Psychostimulants also enhance the performance of execu-
tive functions in subjects with ADHD [9,10] as well as in
typically developed volunteers [11]. The psychostimu-
lants methylphenidate and amphetamine increase the
endogenously produced synaptic dopamine concentra-
tion through inhibition of the dopamine transporter
(DAT), which takes up the dopamine into the presynaptic
neurons [12]. Hence, converging evidence suggests that
the behavioural problems associated with ADHD are
related to cognitive dysfunctions and early disturbances of
the dopamine system innervating the basal ganglia and
the frontal lobe. Genetic and molecular studies have also
demonstrated an association between dopamine related
genes (e.g., dopamine transporter DAT1; dopamine D1
receptor; dopamine D5 receptor; dopamine D4 receptor)
and ADHD [13-18].
The dopamine metabolism in the brain is a function of
the presynaptic synthesis, release and reuptake of
dopamine. Dopamine is synthesized from the amino acid
tyrosine, which is first converted to L-dihydroxyphenyla-
lanine (L-DOPA), and then to dopamine by the enzyme
DOPA decarboxylase. The synthesis has been studied in
vivo in subjects with ADHD with [18F]fluorodopa in two
PET studies [19,20]. In the first of these studies, the
authors found that adult subjects with ADHD had
reduced levels of [18F]fluorodopa in the prefrontal cortex
in comparison with control subjects. In a second study,
they instead reported an increased level of [18F]fluoro-
dopa in the right midbrain in adolescents with ADHD.
Three independent groups, using SPECT, have reported
increased density of the dopamine transporter (DAT) in
the striatum in adults and children with ADHD [21-23].
However, these findings have not been replicated by other
groups reporting unaltered DAT binding in the striatum
[24] and lower DAT binding in the midbrain [25]. Hence,
previous PET and SPECT studies indicate that there is an
abnormal dopamine metabolism in subjects with ADHD,
although the nature of the disturbances remains to be clar-
ified.
In the present study we hypothesized that the behavioural
problems of subjects with ADHD are associated with
altered dopamine synthesis. We used the radio L-
[11C]DOPA, (chemically identical to native L-DOPA),
which is transported into the presynaptic neurons. There
it is converted by the enzyme DOPA decarboxylase to L-
[11C]dopamine and stored in storage vesicles. Therefore,
PET data obtained by L-[11C]DOPA reflect DOPA decar-
boxylase activity and dopamine storage processes. The
properties of the radiotracer L-[11C]DOPA differ in several
important aspects from its more commonly used fluorine
labelled analogue [26]. The turnover rate of L-[11C]DOPA
is state-dependently modulated by drugs that affect
dopaminergic systems and is thus also a measure of the
functional state of the dopaminergic neurons [27-29].
The complicated interactions between different parts of
the dopamine system of the brain, and disparity between
the results from the existing PET studies on ADHD, indi-
cate that straight forward comparisons between individ-
ual brain areas would not be sufficiently sensitive to detect
small abnormalities in the dopamine system. Instead, we
wanted to use the statistical techniques of principal com-
ponent analysis (PCA) and partial least squares regression
(PLS) that allow the examination of multiple brain
regions simultaneously. This statistical technique has a
potential value in detecting correlated changes in different
areas of the brain that normally are not possible using
univariate approaches. Hence, the method of applying the
radiotracer L-[11C]DOPA for multivariate analysis have
many potential applications, such as in the understanding
of drug effects [30]or, as in the present investigation, to
study interaction patterns within the complex dopamine
systems in health and disease.
Methods
Participants
The study was approved by the Ethics Committee and the
Radioisotope Committee of Uppsala University Hospital.
Participation in the study was voluntary, and the subjects
and their parents agreed to participate after receiving
detailed information about the project and the methodol-
ogy. Informed consent was obtained from the subjects or
their parents in accordance with the Declaration of Hel-
sinki.
Study group
The study group included 8 adolescent boys with ADHD
14–15 years of age. They were recruited in cooperation
with child neurologists/psychiatrists at university hospi-
tals in the county of Stockholm. Inclusion criteria were a
clinical diagnosis of ADHD combined type (DSM-IV;
[31], no other neurological condition, and no mental
retardation. Before inclusion, a paediatric neurologist
(EF) interviewed the patients and the parents, confirmed
the diagnosis and rated the severity of symptoms accord-
ing to DSM-IV criteria. The children's attention and hyper-
activity/impulsivity scores (based on the DSM-IV criteria:
0 indicate no problem; 1 minor, 2 moderate, 3 severe
problem; max = 3 × 9 = 27 in the attention and hyperac-
tive/impulsive domain, respectively) are presented in
Table 1). All participants had been tested using WISC-R
[32], conventional test conducted to examine the cogni-
tive level and cognitive profile. All had a full scale IQ of
above 85. One subject had Tourette's syndrome and
another one had dyslexia in addition to the ADHD. All
subjects had been treated with methylphenidate in doses
between 0.1 and 0.6 mg/kg/day (Table 1). One subjectBehavioral and Brain Functions 2006, 2:40 http://www.behavioralandbrainfunctions.com/content/2/1/40
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had finished medication and was not being treated at the
time of the PET study. No other drugs were used. Impor-
tantly, all ADHD subjects were removed from medication
one week prior to the PET investigation.
Comparison group
Six boys 14–16 years of age, without ADHD or any other
neurodevelopmental disorders constituted the compari-
son group.
Tracer chemistry
The synthesis of L-[11C]DOPA was performed according
to the standardized operational procedures at the Uppsala
University PET Centre [33]. The average injected radioac-
tive dose was 306 ± 55 MBq. The radiochemical purity was
95 ± 1% and the dose injected was about 9 µg.
PET scanning procedure
The PET (positron emission tomography) scans were per-
formed at Uppsala University PET Centre with a Siemens
ECAT EXACT HR Plus camera (Siemens Medical Systems,
Knoxville, TN, U.S.A.). The scanning program operated in
3D mode providing 15 continuous slices with a 5 mm
slice thickness and with a spatial resolution of about 5
mm after image reconstruction [34]. The subjects were
positioned in the PET scan with the head gently fixed in
place using a foam head holder that was used for all scans.
The camera was tilted to ensure that the plane of the mid-
dle image corresponded to a line 10 mm below the orbit-
omeatal (OM) line. Before the tracers were injected, a 10-
min transmission scan was performed using an external
68Ga source. To decrease peripheral decarboxylation of
the radiotracer subjects were pre-treated with 100 mg car-
bidopa one hour before the tracer injection. The scanning
was started at the same time as the injection of radiotracer
took place (5 ml normal saline infused over 10 s) and con-
tinued for 59 min.
The technical details used for the scanning were as fol-
lows: the frame length sequence was 3 × 60 s, 3 × 120 s, 3
× 180 s, 5 × 300 s and, finally, 2 × 480 s. Before reconstruc-
tion, the files were attenuation-corrected using data from
the transmission scan, after correction for scattered radia-
tion, and then filtered. The matrix size was 128 × 128 and
the pixel size was 2.0 mm.
Image analysis
Volume-of-distribution images (VD) were reconstructed
from emission data collected 29–59 min after giving the
tracer injection. A standardized ROI (region of interest)
template that was created in-house using MRI (magnetic
resonance imaging) was overlaid on the VD images for
each subject and then manually adjusted to correct for
anatomical differences [30].
The 28 regions included in the ROI template are in the list
of abbreviations. The midbrain section was located in the
mesencephalon in the region of the substantia nigra and
ventral tegmentum. A ROI in the occipital cortex was used
as reference because this region is devoid of dopamine
synthesis. Computer processing was used to determine
the rate of dopamine synthesis by taking the time activity
curve for the occipital cortex, and generating images of the
influx rate, known as Ki images, by performing a weighted
linear regression using a two compartment mathematical
description for the process [35]. As a result, a value for the
unidirectional influx of radioactivity (i.e., dopamine syn-
thesis) was generated for each pixel in a Ki image. Thus,
the Ki values relate to the in vivo synthesis of dopamine in
presynaptic neurons in the brain. The dopamine synthesis
and release was studied in cortical, striatal and midbrain
regions.
Statistical analyses
A PET scan of the brain generates a massive amount of
data. Traditionally such data has been analyzed using uni-
variate approaches, however, such methods cannot take
into account the complexity of the dopamine system or
allow specific profiles of different brain regions to be
made and the interactions between them. The data set,
Table 1: Clinical data of the 8 adolescent boys in the ADHD group.
Subjects Attention score Ha/imp score Medication Dose mg/kg Age (years) at start of treatment Age (years) at PET
11 9 1 4 M p h 0 . 6 1 4 1 5
22 4 2 5 M p h 0 . 3 1 4 1 5
32 2 1 3 M p h 0 . 1 1 5 1 5
42 5 2 2 M p h 0 . 4 1 3 1 4
51 5 2 1 - - - 1 4
62 6 1 7 M p h  S R 0 . 3 1 4 1 4
7* 9 25 Mph SR 0.3 10 15
8 19 21 Mph SR 0.3 9 15
Scores for attention and hyperactivity/impulsivity, respectively, were determined according to DSM-IV (range 0–27 for both). Type, dose and start 
of the psycho stimulant treatment are listed (Mph = methylphenidate, SR = slow release), as well as the age when the PET scan was performed.Behavioral and Brain Functions 2006, 2:40 http://www.behavioralandbrainfunctions.com/content/2/1/40
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comprised of L-[11C]DOPA Ki values, required further
analysis to determine whether there were indeed differ-
ences between the adolescents with and without ADHD.
Thus, the data sets were explored using the statistical tech-
nique partial least squares regression (PLS), which is
closely related to principal components analysis (PCA)
[36,37]. These techniques are generally useful to explore
biological data, which typically display considerable
noise and co-linearity's making the use of e.g. multiple
regression or univariate analysis less adequate. Accord-
ingly, they have widespread use in e.g. imaging and
medicinal chemistry. In essence, PCA and PLS utilizes the
co-variances present among the variables to create a com-
pact and noise-reduced representation of the data. In PLS,
which is used here, one ore more dependent variables are
selected in order to create regression models describing
the relationships between the dependent vs. the inde-
pendent variables. This procedure yields regression coeffi-
cients which are analogous to the coefficients calculated
in e.g. multiple regressions. The statistical significance was
assessed using the cross-validation procedure. This proce-
dure rejects models that are strongly influenced by outly-
ing observations, i.e., such models are not considered
significant. All multivariate calculations were performed
using the Simca-P 10 software (Umetrics Inc., USA).
Standard errors of the regression coefficients were calcu-
lated using the Jack-knife procedure [38]. For average
analysis of regional Ki values STATISTICA for Windows
was used [39]. The Sheffe F-test was used for post hoc test-
ing. The level of significance was set to P  < 0.05.
Results
The ADHD subjects displayed lower Ki values in most
regions than the control group (Table 2). However, in an
Anova analysis, only the midbrain section showed a sig-
nificant decrease compared to the controls. Since the
Anova approach is not ideal for the analysis of several
simultaneous measurements, the dataset was further ana-
lyzed using multivariate analysis. To compare the ADHD
and control groups, PLS analysis was performed with a
discriminant variable incorporated denoting a diagnosis
of having ADHD or of not having ADHD. The analysis
yielded a statistically significant one-component model
separating the ADHD subjects from the controls (R2X =
0,27, R2Y = 0.43, Q2 = 0.081). The subjects are clearly dis-
tributed in two groups (Figure 1).
The PLS regression coefficient indicates which variables
are most responsible for the separation of the two groups
(Figure 2). Such coefficients are interpreted in the same
way as in ordinary regression analysis and, consequently,
positive coefficients indicate positive correlations and the
size of the coefficient reflects the strength of the correla-
tion. In this case, the dependent variable is a discriminant
variable denoting the ADHD diagnosis, so that positive
coefficients indicate increases in comparison with the
control group, and negative coefficients indicate
decreases. Thus, the dominance of negative columns in
Figure 2 shows that ADHD subjects generally have lower
Ki. Furthermore, the regression coefficients suggest that
predominantly subcortical Ki values (dark blue) are low,
while cortical Ki values (light blue) are less affected.
To further explore the relationship between the Ki indices
and ADHD symptoms, a PLS regression model was cre-
ated. This describes the dependence of the attention score
(obtained using DSM-IV) on the Ki indices in the ADHD
patients. The attention scores were taken as the Y varia-
bles, and Ki values as the X variables. One patient with a
remarkably low attention (an outlier) who exhibited a
good response to methylphenidate was excluded from
this regression model (see patient 7; Table 1). The model
was statistically significant, indicating a strong relation
between Ki and attention (R2Xcum = 0.46, R2Ycum = 0.982,
Q2
cum = 0.726 for the two first components). The R2Ycum
statistic is analogous to the coefficient of determination
(R2) used in correlation analysis. In this model, R2Y is
large, 98%, reflecting a strong correlation between the Ki
and the attention score data. The relations between Ki val-
ues and attention are further visualized in Figure 3, where
the PLS regression coefficients are shown. Most cortical
variables tend to be positively related to attention,
whereas the subcortical Ki indices, with few exceptions,
are negatively correlated to attention. Thus, low subcorti-
cal Ki values are associated both with the ADHD diagnosis
per se, as demonstrated by the first PLS model (Figure 2),
and with more severe attention deficits within the ADHD
group (Figure 3). Cortical variables appear to be less
important with respect to group discrimination, but have
a positive correlation to attention within the ADHD
group. When patient 7 with the deviating score was
included, the model showed the similar trend, but did not
reach significance due to the increased variation in the
small sample (n = 8).
An attempt to model the hyperactivity/impulsivity  score
(DSM-IV) in relation to regional Ki values in a similar way
failed to produce a significant model. Thus, we find no
association between regional dopamine synthesis and
hyperactivity/impulsivity. With the data at hand we can-
not determine whether this is due to a true lack of associ-
ation, or if e.g. a large noise level in the hyperactivity/
impulsivity scores, or heterogeneity in the ADHD popula-
tion, obscures the relationship.
Discussion
Bearing in mind the limitations of this study (see below),
we have shown that it is possible to distinguish ADHD
subjects from age matched controls by applying multivar-
iate statistical methods to regional L-[11C]DOPA Ki val-Behavioral and Brain Functions 2006, 2:40 http://www.behavioralandbrainfunctions.com/content/2/1/40
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Table 2: Regional L-[11C]DOPA influx rate (Ki*10) in the 28 regions included in the ROI template (see list of abbreviations) in the 
ADHD and control groups.
Region Controls ADHD Diff (%)
rlrl
Caudd 1,62 1,60 1,50 1,47 -7,3 -8,0
Caudint 1,67 1,65 1,64 1,61 -1,8 -2,7
Caudv 1,76 1,77 1,66 1,65 -5,4 -6,6
Putd 1,36 1,49 1,48 1,55 8,6 3,4
Putint 1,87 1,88 1,67 1,82 -10,7 -3,0
Putv 1,93 1,87 1,73 1,73 -10,4 -7,2
Mpfd 0,66 0,61 0,61 0,63 -8,0 4,2
Mpfi 0,64 0,60 0,61 0,63 -5,4 5,5
Mpfv 0,64 0,63 0,61 0,56 -4,7 -10,0
Pfd 0,46 0,45 0,42 0,45 -8,1 -0,3
Pfi 0,46 0,45 0,42 0,45 -9,9 -0,3
Pfv 0,44 0,48 0,47 0,47 6,5 -2,4
Acc 1,77 1,81 1,54 1,61 -12,7 -11,0
Midbrain 0,90 0,88 0,75* 0,66* -17,2 -24,9
The difference between the groups for each region is expressed in percentage. Only midbrain values reached statistical significance (ANOVA).
Partial least squares regression (PLS) discriminant analysis distinguishes ADHD patients (red circles) from control subjects  (black squares) Figure 1
Partial least squares regression (PLS) discriminant analysis distinguishes ADHD patients (red circles) from control subjects 
(black squares). Each object in the graph represents one individual. For each individual, the position in the plot is a compact 
representation of all regional Ki data collected. Objects that appear close to each other are generally similar across all variables. 
In this case, ADHD patients and controls form separate groups, reflecting underlying group differences in regional Ki values.
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Regression coefficients in the PLS model discriminating ADHD patients vs. control subjects Figure 2
Regression coefficients in the PLS model discriminating ADHD patients vs. control subjects. A large positive coefficient indi-
cates an increase in the corresponding variable in ADHD patients vs. controls. In this model, most coefficients are negative, 
reflecting a general decrease in Ki values in the ADHD group. In particular, subcortical Ki values (dark blue columns) tend to be 
negatively related to the ADHD diagnosis. See list of abbreviations to identify the anatomical ROIs
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Regression coefficients in the PLS model relating attention score to regional Ki values in the ADHD group only Figure 3
Regression coefficients in the PLS model relating attention score to regional Ki values in the ADHD group only. Large positive 
coefficients indicate a positive correlation, i.e., the larger the Ki, the higher the attention score. Large negative coefficients sug-
gest an inverse relationship, where high Ki values are associated with low values in the attention score.
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ues. In most brain areas in the subjects with ADHD the
rate of dopamine synthesis was lower than in the healthy
controls, with the values being particularly low in the sub-
cortical regions. The low synthesis in the subcortical areas
correlates with the severity of the attention deficit symp-
toms, assessed according to the DSM-IV. These findings
are in good agreement with extensive experimental and
clinical research supporting the notion that dopamine sys-
tem plays a modulatory role in attention processes, while
impulse control is more linked to other neurotransmitter
systems, e.g., serotonin [40]
There are several limitations of this study. Most of our
subjects with ADHD were not drug naïve, and although
all were medication-free for at least 1 week, the washout
period may not have been sufficient to reset the dopamine
system to a basal level. In addition, psychostimulants are
known to produce long term effects, e.g., dendrite growth
in prefrontal cortex of rodents [41] and down-regulation
of the dopamine D2 receptor in primates [42]. Therefore,
at this point we cannot exclude any effects of the medica-
tion and therefore new studies need to be performed on
drug naïve subjects. Moreover, two of the subjects with
ADHD had additional neurological disorders. In particu-
lar, the subject with Tourette's syndrome could be a con-
founder since this condition is associated with abnormal
dopamine metabolism [43]. However, it should be noted
that the method used to establish statistical significance of
the multivariate models, cross-validation, is based on the
calculation of how stable the results are as different sub-
jects are excluded. Models in which the relationships
observed rely on "outliers" will therefore not be consid-
ered statistically significant by the cross-validation crite-
rion. Exclusion of the two comorbid cases did not affect
the results. Hence, although the sample size is small and
includes individuals with comorbid conditions, the appli-
cations of multivariate statistical methods are able to
demonstrate significant results.
The low L [11C]DOPA Ki values suggest that children with
ADHD differ from controls in their metabolism of DOPA
over a range of cortical and subcortical regions. It is most
likely that the low values reflect aberrations in the presyn-
aptic synthesis and release of dopamine. These results
support earlier theories that a hypofunction of the
dopamine system underlies the behavioural symptoms in
ADHD [44]. This theory was based on the positive effects
of stimulant drugs in children with ADHD and that such
drugs facilitate the endogenous monoamine transmission
by blocking the dopamine transporter. Later, Volkow and
co-workers have in a series of elegant PET studies shown
that methylphenidate increases the endogenous level of
dopamine and that it interacts with mental tasks trigger-
ing dopamine release [45,46]. However, there has been
little support for lower dopamine synthesis in previous
SPECT and PET studies in subjects with ADHD. PET stud-
ies on the uptake of [18F]fluorodopa have demonstrated
that there is a decreased uptake in the frontal cortex and an
increased uptake in the midbrain [19,20]. The latter result
is opposite to ours, obtained by studying the uptake of L-
[11C]DOPA. The differences might be attributable to the
different specificity of the radioligands. As a radiotracer, L-
[11C]DOPA seems to detect changes in the functional tone
in the dopaminergic systems more readily than its fluo-
rine labelled analogue [26].
Other SPECT and PET studies of dopamine transporter
binding in ADHD have reported increased binding capac-
ity in the striatum of adults and children with ADHD [21-
23,47]. However, this result was not replicated by other
groups, who instead reported either an unaltered or a
reduced DAT- binding [24,48]. In a recent PET study on
adolescent boys with ADHD, we used a newly developed
cocaine analogue radioligand, [11C]PE2I, that binds selec-
tively to the dopamine transporter [25,49]. We could not
confirm the first SPECT studies indicating an increased
DAT binding in striatum, but rather obtained results more
closely in agreement with the studies indicating an unal-
tered or decreased binding capacity. In addition, the high
performance of 3D PET and the good characteristics of the
new radioligand allowed us to detect a clear reduction of
the DAT binding in the midbrain. These two recent studies
from our group, indicating a lower dopamine synthesis
and a reduced density of DAT in the midbrain, correspond
well to the earlier theories of reduced dopamine signalling
[44]. From our results it is not possible to determine the
primary cause of the imbalance. A reduction of the presy-
naptic dopamine synthesis and release could be compen-
sated for by decreased DAT activity. Genetic studies in
subjects with ADHD have identified polymorphism in
several specific genes that encode components of catecho-
lamine signalling system, among them polymorphism in
the DAT gene [13]. In some subjects, a lower uptake of
dopamine from the synaptic cleft may thus be the primary
cause. This could subsequently induce secondary adapta-
tions of the dopamine release and synthesis via presynap-
tic autoreceptors [50]. Recently, in an animal model of
ADHD (using the spontaneously hypertensive rat), the
expression of specific genes involved in dopamine neuron
differentiation and functioning during the postnatal
development of the midbrain was studied [51]. The data
showed transient reductions of the expression of tyrosine
hydroxylase and dopamine transporter genes, suggesting
a down-regulation of the dopamine transmission at this
stage of development, which is in line with the present
study and which supports the hypodopaminergic hypoth-
esis of ADHD.
In the present study, ADHD subjects tended to display
lower Ki values over most regions. However, with closerBehavioral and Brain Functions 2006, 2:40 http://www.behavioralandbrainfunctions.com/content/2/1/40
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examination, a region-specific pattern emerges. The most
profound decreases are seen in subcortical areas (Figure 2
and Table 1), such as the nucleus accumbens, putamen
and the midbrain, while cortical areas show smaller
decreases, and even a tendency towards increases in some
prefrontal areas. This indicates that there are regional dif-
ferences and that the ADHD specific alteration of the
dopamine synthesis is region specific. The possibility of
different dopamine abnormalities in different brain
regions in ADHD has been discussed previously by, e.g.,
Castellanos [52], who suggested that there was a differ-
ence between areas innervated by the two dopamine path-
ways originating from the substantia nigra and the ventral
tegmental area, respectively. The motor hyperactivity and
impulsivity could be caused by overactivity in the basal
ganglia, innervated by the substantia nigra, while the inat-
tention could be due to an underactivity in the cortical
areas innervated by the ventral tegmentum. Our data cor-
responds with this hypothesis to a certain extent, i.e., our
data indicate that the DOPA metabolism in the basal gan-
glia seems to have a different pattern to that in the cortical
areas. However, our data on the DOPA metabolism is
hard to translate into terms of increased or reduced activ-
ity in the neural networks controlling the functional activ-
ity because the dopamine may have both facilitatory and
inhibitory effects, depending on, e.g., the profile of the
local dopamine receptor population on the postsynaptic
neurons [53].
There was a strong relationship between attention and the
regional Ki values within the ADHD Group. First, the
results indicate that the Ki pattern not only discriminates
between the ADHD group and the controls, but that it is
also related to the severity of the attention difficulties of
the individuals with ADHD. Most subcortical Ki values are
inversely related to attention, i.e., the lower the Ki values
the more problems the subject has with inattention. Con-
versely, in several cortical regions the Ki are positively
related to the severity of symptoms. Again, it appears that
the subcortical and cortical DA systems are differentially
affected in patients with ADHD and that the resulting
behavioural effects differ.
Most PET and SPECT studies on ADHD subjects have so
far indicated that there are disturbances both in the pre-
and postsynaptic dopamine transmission, but the results
have been inconsistent. The reasons for these discrepan-
cies probably reflect the use of different imaging tech-
niques (PET and SPECT) and different radioligands, as
well as differences in the age and medication history of
the populations studied. A fundamental problem exists in
addition to this, which is that the ADHD construct is
based on behavioural symptoms and therefore includes
heterogeneous populations of children with different cog-
nitive and behavioural dysfunctions. This functional vari-
ation is probably associated with certain molecular
variations in specific brain areas that may be large in rela-
tion to a more subtle general difference between ADHD
subjects and controls. In the work reported here, it was
only possible to reveal a general pathological pattern of
the complex dopamine system that is shared by subjects
with core ADHD symptoms by conducting multivariate
analysis on data obtained by PET.
Conclusion
Attempts to create a single theory explaining ADHD have
failed so far. This is not remarkable in view of the present
study, revealing the complexity of the interaction between
the dopamine synthesis in the various subcortical and cor-
tical areas and between this interactive pattern and the
symptoms of attention deficit. We have only studied one
component in the complex chain of dopamine signalling.
It is obvious that the neurobiological mechanisms under-
lying ADHD are numerous and interactive. The challenge
for future research is to characterize various subtypes of
ADHD and, in particular, to determine the underlying
cognitive dysfunctions and their interaction with various
neural and neurotransmitter systems.
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